Brentuximab
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells[1][2][3].
Product Specifications
CAS Number
2088770-90-3
UNSPSC
12352203
Target
ADC Antibody; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brentuximab.html
Purity
99.64
Solubility
10 mM in DMSO
Smiles
[Brentuximab]
Molecular Weight
(145.48 kDa)
References & Citations
[1]Bhatt S, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013 Aug 15;122 (7) :1233-42. |[2]Chen R W, et al. Inhibition of MDR1 overcomes brentuximab vedotin resistance in Hodgkin lymphoma cell line model and is synergistic with brentuximab vedotin in mouse xenograft model[J]. Blood, 2016, 128 (22) : 752.|[3]Wang Z, et al. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 Jul;13 (7) :1309-1319.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4
Isoform
TNFRSF8/CD30
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K6575602 1.0 µg DNA
Smyd4 sgRNA CRISPR Lentivector (Rat) (Target 1)
Sign In for Pricing
View Details 
